FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136501523> ?p ?o ?g. }

• W2136501523 endingPage "2" @default.
• W2136501523 startingPage "1" @default.
• W2136501523 abstract "Photodynamic therapy (PDT) involves the activation of a photosensitizing drug by visible light to produce activated oxygen species which promote tumour destruction. Despite a rising tide of publications in recent years, PDT was first described 100 years ago. Generalized and severe phototoxicity from early crude photosensitizers limited development, although partial purification produced a haematoporphyrin derivative, with the first human trial, which included basal cell carcinomas, performed almost 25 years ago. However, generalized photosensitivity could persist for up to 8 weeks, a strong deterrent to dermatological applications for which alternative therapies existed, although the commercial, partly purified formulation, Photofrin, has been approved in several countries for early and advanced pulmonary and oesophageal cancer. The use of a topically effective agent, 5-aminolaevulinic acid (5-ALA), has triggered the current wave of enthusiasm towards PDT. Exogenous 5-ALA increases the intracellular production of the endogenous photosensitizer protoporphyrin IX, via the haem pathway, with preferential accumulation in neoplastic tissue. Topical ALA±PDT appears particularly effective in actinic keratoses of the face and scalp, and in Bowen's disease, where advantages over conventional therapy regarding adverse events and cosmesis have been demonstrated. Published clearance rates for ALA±PDT in basal cell carcinomas (BCCs) range from 79 to 100% for clinically superficial lesions and 10±75% for nodular lesions, with lesions less than 2 mm thick on diagnostic biopsy achieving a superior outcome. Examination of the fluorescence emitted by ALA-induced PpIX has shown full thickness fluorescence in 6/7 superficial and 4/9 nodular BCCs after 20% ALA application and partial superficial fluorescence in the five remaining nodular BCCs. A complete clearance rate (CCR) of 96% at 12 months for superficial BCCs has demonstrated the importance of technique, with two treatments 7 days apart yielding results superior to the same group's 50% CCR after a single treatment. Two other topically active photosensitizers have been evaluated. Topical meso-tetraphenylporphinesulphonate tetrasodium (mTPPS) cleared 94% of 292 superficial BCCs on a single treatment with a 10% recurrence rate. Topical meta-tetrahydroxyphenylchlorin (mTHPC) has also been assessed in a pilot study in Bowen's disease and superficial BCC, but with disappointing results, achieving histological clearance rates of 32% and 29%, respectively, suggesting that systemic application may be required. Baas et al. in this issue describe a phase I/II study of PDT using systemic mTHPC to treat 187 lesions in five patients with multiple superficial BCCs, including two with naevoid basal cell carcinoma syndrome. A lightemitting diode device was employed and treatment times ranged from 50 to 150 s, with complete response rates at 12 months of up to 86%. Photosensitivity limited patients to subdued lighting conditions for 1 week and restrictions on sunlight exposure for a second week. mTHPC can achieve tumour necrosis to a depth of 1 cm with red light at 652 nm suggesting that even thick nodular BCC might be effectively targeted. Systemic mTHPC-PDT might thus be best developed for nodular and/or multiple BCC, where topical ALA-PDT is limited in efficacy and practicality, although restrictions on light exposure will remain a concern for patient and doctor. Other second generation photosensitisers, e.g. benzoporphyrin derivative-monoacid, are likely also to be evaluated for these indications. The challenge to the dermatologist remains to optimize outcomes following topical PDT. Soler et al. have reported the clearance of 92% of 119 nodular BCC $ 2 mm thick following debulking curettage prior to ALA±PDT (also using dimethylsulphoxide)." @default.
• W2136501523 created "2016-06-24" @default.
• W2136501523 creator A5008344609 @default.
• W2136501523 date "2001-07-01" @default.
• W2136501523 modified "2023-09-26" @default.
• W2136501523 title "Treating basal cell carcinoma: has photodynamic therapy come of age?" @default.
• W2136501523 cites W2007299129 @default.
• W2136501523 cites W2013294070 @default.
• W2136501523 cites W2046269437 @default.
• W2136501523 cites W2050834369 @default.
• W2136501523 cites W2066097192 @default.
• W2136501523 cites W2080795148 @default.
• W2136501523 cites W2091210609 @default.
• W2136501523 cites W2103857207 @default.
• W2136501523 cites W2105820114 @default.
• W2136501523 cites W2119492226 @default.
• W2136501523 cites W2152440750 @default.
• W2136501523 cites W2402598604 @default.
• W2136501523 doi "https://doi.org/10.1046/j.1365-2133.2001.04372.x" @default.
• W2136501523 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11453899" @default.
• W2136501523 hasPublicationYear "2001" @default.
• W2136501523 type Work @default.
• W2136501523 sameAs 2136501523 @default.
• W2136501523 citedByCount "9" @default.
• W2136501523 countsByYear W21365015232013 @default.
• W2136501523 countsByYear W21365015232015 @default.
• W2136501523 countsByYear W21365015232022 @default.
• W2136501523 crossrefType "journal-article" @default.
• W2136501523 hasAuthorship W2136501523A5008344609 @default.
• W2136501523 hasBestOaLocation W21365015231 @default.
• W2136501523 hasConcept C126322002 @default.
• W2136501523 hasConcept C143998085 @default.
• W2136501523 hasConcept C16005928 @default.
• W2136501523 hasConcept C178790620 @default.
• W2136501523 hasConcept C185592680 @default.
• W2136501523 hasConcept C2778804307 @default.
• W2136501523 hasConcept C2781323092 @default.
• W2136501523 hasConcept C3019992690 @default.
• W2136501523 hasConcept C71924100 @default.
• W2136501523 hasConceptScore W2136501523C126322002 @default.
• W2136501523 hasConceptScore W2136501523C143998085 @default.
• W2136501523 hasConceptScore W2136501523C16005928 @default.
• W2136501523 hasConceptScore W2136501523C178790620 @default.
• W2136501523 hasConceptScore W2136501523C185592680 @default.
• W2136501523 hasConceptScore W2136501523C2778804307 @default.
• W2136501523 hasConceptScore W2136501523C2781323092 @default.
• W2136501523 hasConceptScore W2136501523C3019992690 @default.
• W2136501523 hasConceptScore W2136501523C71924100 @default.
• W2136501523 hasIssue "1" @default.
• W2136501523 hasLocation W21365015231 @default.
• W2136501523 hasLocation W21365015232 @default.
• W2136501523 hasOpenAccess W2136501523 @default.
• W2136501523 hasPrimaryLocation W21365015231 @default.
• W2136501523 hasRelatedWork W1506375529 @default.
• W2136501523 hasRelatedWork W1964723420 @default.
• W2136501523 hasRelatedWork W1994913176 @default.
• W2136501523 hasRelatedWork W2095043843 @default.
• W2136501523 hasRelatedWork W2168505568 @default.
• W2136501523 hasRelatedWork W2385537546 @default.
• W2136501523 hasRelatedWork W2598506241 @default.
• W2136501523 hasRelatedWork W2936428995 @default.
• W2136501523 hasRelatedWork W3032728671 @default.
• W2136501523 hasRelatedWork W2593957515 @default.
• W2136501523 hasVolume "145" @default.
• W2136501523 isParatext "false" @default.
• W2136501523 isRetracted "false" @default.
• W2136501523 magId "2136501523" @default.
• W2136501523 workType "article" @default.